ITBA920007A1 - PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES - Google Patents
PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONESInfo
- Publication number
- ITBA920007A1 ITBA920007A1 IT92BA000007A ITBA920007A ITBA920007A1 IT BA920007 A1 ITBA920007 A1 IT BA920007A1 IT 92BA000007 A IT92BA000007 A IT 92BA000007A IT BA920007 A ITBA920007 A IT BA920007A IT BA920007 A1 ITBA920007 A1 IT BA920007A1
- Authority
- IT
- Italy
- Prior art keywords
- hormones
- pharmaceutical formulations
- estrogenic
- systemic administration
- natural
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title abstract 3
- 239000005556 hormone Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000007910 systemic administration Methods 0.000 title abstract 2
- 239000003163 gonadal steroid hormone Substances 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 3
- 230000001076 estrogenic effect Effects 0.000 abstract 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 208000019255 Menstrual disease Diseases 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 239000006196 drop Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229960001348 estriol Drugs 0.000 abstract 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
- 229960003399 estrone Drugs 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 230000001072 progestational effect Effects 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 239000003270 steroid hormone Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Abstract
L'invenzione riguarda formulazioni farmaceutiche atte alla somministrazione sistemica per via nasale, cioè attraverso la mucosa nasale, degli ormoni steroidei naturali femminili (17-beta estradiolo, estriolo, estrone e progesterone), o ai loro derivati ed anche di tutte le molecole, sia naturali che di sintesi, ad attività estrogenica c/o progestativa. la somministrazione per via nasale può essere effettuata mediante spray, soluzioni, sospensioni, gocce, unguento e gel la formulazione combinata della componente ad attività estrogenica con quella ad attività progestativa può essere particolarmente utile a scopo contraccettivo; le formulazioni contenenti solo uno degli ormoni considerati possono trovare vasto impiego singolarmente o in associazione nel trattamento della menopausa, dei disturbi mestruali, nelle situazioni di ipogonadismo, per il mantenimento della gravidanza ed in generale in tutti i casi che sono noti rispondere ed essere comunemente trattati con ormoni ad attività estrogenica e/o progestinica.The invention relates to pharmaceutical formulations suitable for the systemic administration of the female natural steroid hormones (17-beta estradiol, estriol, estrone and progesterone), or their derivatives and also of all molecules, via the nasal mucosa. natural and synthetic, with estrogenic c / o progestative activity. nasal administration can be carried out by means of sprays, solutions, suspensions, drops, ointment and gel. the combined formulation of the estrogenic component with the progestational one can be particularly useful for contraceptive purposes; formulations containing only one of the hormones considered can be widely used individually or in association in the treatment of menopause, menstrual disorders, in hypogonadism situations, for the maintenance of pregnancy and in general in all cases that are known to respond and be commonly treated with hormones with estrogenic and / or progestin activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT92BA000007A ITBA920007A1 (en) | 1992-03-20 | 1992-03-20 | PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT92BA000007A ITBA920007A1 (en) | 1992-03-20 | 1992-03-20 | PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITBA920007A0 ITBA920007A0 (en) | 1992-03-20 |
| ITBA920007A1 true ITBA920007A1 (en) | 1993-09-20 |
Family
ID=11335421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT92BA000007A ITBA920007A1 (en) | 1992-03-20 | 1992-03-20 | PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITBA920007A1 (en) |
-
1992
- 1992-03-20 IT IT92BA000007A patent/ITBA920007A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ITBA920007A0 (en) | 1992-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4383993A (en) | Nasal dosage forms containing natural female sex hormones | |
| US4315925A (en) | Method of administering natural female sex hormones | |
| Saez et al. | Further in vivo studies in male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect (compared to a case of testicular feminization) | |
| AU5388494A (en) | Therapeutic methods & delivery systems utilizing sex steroid precursors and novel steroidal derivatives and pharmaceutical compositions thereof | |
| CA2154161A1 (en) | Therapeutic uses and delivery systems of dehydroepiandrosterone | |
| US4177267A (en) | Enhancing tissue penetration of physiologically active steroidal agents with DMSC | |
| NO975586L (en) | Transdermal device and method for administering 17-deacetyl norestimate alone or in combination with an estrogen | |
| BR9911411A (en) | Transdermal drug delivery system of the matrix type with high rates of distribution of steroid hormones and use of this system for hormone replacement therapy | |
| AR031563A1 (en) | A PHARMACEUTICAL COMPOSITION FOR EMPLOYMENT IN THE TREATMENT OF MENOPAUSIC OR POSMENOPAUSIC DISORDERS OF STROGENS AND MEDROXIPROGESTERONE ACETATE, A PHARMACEUTICAL DOSAGE UNIT AND USE OF A CONJUGATED STRAGEN COMBINATION OF UTROGRAPHIC MANIFORM | |
| MA26834A1 (en) | NEW CONTRACEPTIVE MEDICINAL PRODUCT AND ITS PREPARATION METHOD | |
| BR9709934A (en) | Hormone replacement therapy kit and / or contraceptive use of daily dosage units consisting essentially of a progestogen and process of preparing a drug delivery system | |
| DE69133214D1 (en) | MEDICINES FOR THE TOPICAL USE OF SEXUAL HORMONES FOR TREATING THE DRY EYE, AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| NO954611L (en) | Methods and preparations for use in the treatment of benign gynecological diseases | |
| PT854705E (en) | METHOD OF THERAPY OF HORMONAL REPLACEMENT AND RESPECTIVE DISPENSER | |
| Ulmann | Uses of RU 486 for contragestion: an update | |
| BR0008076A (en) | 16-hydroxyestratrienes as selective effect estrogens | |
| ITBA920007A1 (en) | PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES | |
| Strauss et al. | The effect of ACTH and hydrocortisone on the human sebaceous gland | |
| US5993782A (en) | Therapeutic method for reversing hyposmia in a human patient | |
| HUP0101005A2 (en) | Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor | |
| KR20010102464A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
| Lutsik | Effect of combined synthetic progestins on blood coagulation properties and alpha 2-glycoprotein content | |
| GB1225830A (en) | ||
| GB1430223A (en) | Anti-inflammatory composition comprising steroids | |
| ITMI950625A1 (en) | PHARMACEUTICAL COMPOSITION ACTIVE IN THE TREATMENT OF DERMATOLOGICAL DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0002 | Rejected |